Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

899 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C, Moretti A, Galassi R, Rossi L, Amadori D, Paganelli G, Matteucci F. De Giorgi U, et al. Among authors: moretti a. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1276-83. doi: 10.1007/s00259-015-3042-5. Epub 2015 Mar 26. Eur J Nucl Med Mol Imaging. 2015. PMID: 25808631
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P, De Giorgi U, Scarpi E, Fantini L, Moretti A, Galassi R, Celli M, Conteduca V, Rossi L, Bianchi E, Paganelli G, Matteucci F. Caroli P, et al. Among authors: moretti a. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):348-354. doi: 10.1007/s00259-017-3866-2. Epub 2017 Nov 6. Eur J Nucl Med Mol Imaging. 2018. PMID: 29110067 Clinical Trial.
Erratum to: (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C, Moretti A, Galassi R, Rossi L, Amadori D, Paganelli G, Matteucci F. De Giorgi U, et al. Among authors: moretti a. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1337-8. doi: 10.1007/s00259-015-3069-7. Eur J Nucl Med Mol Imaging. 2015. PMID: 25900277 No abstract available.
Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results.
Matteucci F, Mezzenga E, Caroli P, Di Iorio V, Sarnelli A, Celli M, Fantini L, Moretti A, Galassi R, De Giorgi U, Paganelli G. Matteucci F, et al. Among authors: moretti a. Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2189-2194. doi: 10.1007/s00259-017-3791-4. Epub 2017 Aug 11. Eur J Nucl Med Mol Imaging. 2017. PMID: 28801787
Evaluation of in vivo labelled dendritic cell migration in cancer patients.
Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Moretti A, Migliori G, Fiorentini G. Ridolfi R, et al. Among authors: moretti a. J Transl Med. 2004 Jul 30;2(1):27. doi: 10.1186/1479-5876-2-27. J Transl Med. 2004. PMID: 15285807 Free PMC article.
899 results